Showing results (1-10 of 27) with videos related to
Sort By:
Pageof 3
Expert Opinion on Pharmacotherapy|August 29, 2017
Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosisKatja Thomas, Undine Proschmann, Tjalf ZiemssenFrontiers in Neurology|May 3, 2021
Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple SclerosisUndine Proschmann, Hernan Inojosa, Katja Akgün, et al.Frontiers in Neurology|February 8, 2021
Should We Use Clinical Tools to Identify Disease Progression?Hernan Inojosa, Undine Proschmann, Katja Akgün, et al.Therapeutic Advances in Chronic Disease|January 24, 2022
The need for a strategic therapeutic approach: multiple sclerosis in checkHernan Inojosa, Undine Proschmann, Katja Akgün, et al.Cells|November 27, 2021
Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side EffectsStefanie Fischer, Undine Proschmann, Katja Akgün, et al.Journal of Neurology|August 1, 2019
A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definitionHernan Inojosa, Undine Proschmann, Katja Akgün, et al.Frontiers in Immunology|September 13, 2021
Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and LactationUndine Proschmann, Rocco Haase, Hernan Inojosa, et al.Frontiers in Immunology|December 8, 2018
Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated PatientsMaxi Kaufmann, Rocco Haase, Undine Proschmann, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2017
Natalizumab during pregnancy and lactationUndine Proschmann, Katja Thomas, Sandra Thiel, et al.Frontiers in Immunology|June 28, 2024
Corticosteroid-depending effects on peripheral immune cell subsets vary according to disease modifying strategies in multiple sclerosisLena Höpner, Undine Proschmann, Hernan Inojosa, et al.Pageof 3